Indoline derivatives II: Synthesis and factor Xa (FXa) inhibitory activities

Chemical and Pharmaceutical Bulletin

Volumn 55, Issue 3, 2007, Pages 393-402

  Noguchi, Tetsuji ^a   Tanaka, Naoki ^a   Nishimata, Toyoki ^a   Goto, Riki ^a   Hayakawa, Miho ^a   Sugidachi, Atsuhiro ^a   Ogawa, Taketoshi ^a   Asai, Fumitoshi ^a   Ozeki, Tomoko ^a   Fujimoto, Koichi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Anticoagulant; Factor Xa (FXa) inhibitory activity; Indoline derivative

Indexed keywords

5 [1 (ACETYMIDOYL)PIPERIDIN 4 YLOXY] 2 (7 AMIDINONAPHTHALEN 2 YL) 1 (ETHANESULFONYL)INDOLINE; [(5 [1 (ACETIMIDOYL)PIPERIDIN 4 YLOXY] 2 (7 AMIDINONAPHTHALEN 2 YL) INDOLIN 1 YL)SULFONYL]ACETIC ACID DIHYDROCHLORIDE; [5 [1 (ACETYMIDOYL)PIPERIDIN 4 YLOXY] 2 (7 AMIDINONAPHTHALEN 2 YL)INDOLIN 1 YL]SULFONYL ACETIC ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; ETHANESULFOYL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SAFETY; DRUG SYNTHESIS; HAMSTER; IN VITRO STUDY; MOUSE; NONHUMAN;

ANIMALS; ANTICOAGULANTS; CALLITHRIX; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HUMANS; INDOLES; MACACA FASCICULARIS; MICE; MOLECULAR STRUCTURE;

EID: 34047126829     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.55.393     Document Type: Article

References (24)

1. Harder S., Thurmann P., Clin. Pharmacokinet., 30, 416-444 (1996).
2. Hirsh J., N. Engl. J. Med., 324, 1865-1875 (1991).
3. Wells P. S., Holbrook A. M., Crowther N. R., Hirsh J., Ann. Intern. Med., 121, 676-683 (1994).
4. Elodi S., Varadi K., Thromb. Res., 15, 617-629 (1979).
5. Hara T., Yokoyama A., Tanabe K., Ishihara H., Iwamoto M., Thromb. Haemost., 1995, 635-639 (1995).
6. Sato K., Taniuchi Y., Kawasaki T., Hirayama F., Koshio H., Matsumoto Y., Iizumi Y., Jpn. J. Pharmacol., 1998, 191-197 (1998).
7. Noguchi T., Tanaka N., Nishimata T., Goto R., Hayakawa M., Sugidachi A., Ogawa T., Asai F., Matsui Y., Fujimoto K., Chem. Pharm. Bull., 54, 163-174 (2006).
8. Tsunoda T., Yamamiya Y., Ito S., Tetrahedron Lett., 34, 1639-1642 (1993).
9. Mitsunobu O., Synthesis, 1981, 1-28 (1981).
10. Judkins B. D., Allen D. G., Cook T. A., Evans B., Sardharwala T. E., Synth. Commum., 26, 4351-4367 (1996).
11. 1H-NMR spectra.
12. Bartori G., Bosco M., Dalpozzo R., Todesco E. P., J. Org. Chem., 51, 3694-3696 (1986).
13. Huang W., Zhang P., Zuckett J. F., Wang L., Woolfrey J., Song Y., Jia Z. J., Clizbe L. A., Su T., Tran K., Huang B., Wong P., Sinha U., Park G., Reed A., Malinowski J., Hollenbach S. J., Scarborough R. M., Zhu B., Bioorg. Med. Chem. Lett., 13, 561-566 (2003).
14. Echavarren A. M., Stille J. K., J. Am. Chem. Soc., 109, 5478-5486 (1987).
15. Oh-e T., Miyaura N., Suzuki A., J. Org. Chem., 58, 2201-2208 (1993).
16. Vice S., Bara T., Bauer A., Evans C. A., Ford J., Josien H., McCombie S., Miller M., Nazareno D., Palani A., Tagat J., J. Org. Chem., 66, 2487-2492 (2001).
17. Ting P. C., Lee J. F., Wu J., Umland S. P., Aslanian R., Cao J., Dong Y., Garlisi C. G., Gilbert E. J., Huang Y., Jakway J., Kelly J., Liu Z., McCombie S., Shah H., Tian F., Wan Y., Shih N.-Y., Bioorg. Med. Chem. Lett., 15, 1375-1378 (2005).
18. 24,25) In spite of many efforts, the reaction was result in recovery of compound 24.
19. Han F., Hayashi M., Watanabe Y., Eur. J. Org. Chem., 2004, 558-566 (2004).
20. In the previous report, (S)-3 was obtained from separation of (RS)-3 by preparative chiral HPLC. (S)-3 was converted to compound (R)-35, then we determined the stereochemistry of (R)-35 and (S)-3 (the starting material of (R)-35) by X-ray crystallographic analysis of (R)-35. This time, each retention time of (S)-3 and (R)-3 was already in hand, so we determined their stereochemistry by comparison of its retention time. (Chemical Equation Presented)
21. Oliver J. E., DeMilo A. B., Synthesis, 1975, 321-322 (1975).
22. max (10 min) was 7.0 mg/ml. As a result, no significant difference was observed in plasma concentration of both compounds. This result indicates that the difference of toxicity between (RS)-1 and 11d isn't induced by the plasma concentration but these compounds themselves (unpublished data).
23. Guram A. F., Rennels R. A., Buchwald S. L., Angew. Chem. Int. Ed. Engl., 1995, 1348-1350 (1995).
24. Wolfe J. P., Buchwald S. L., J. Org. Chem., 1997, 1264-1267 (1997).